SC
IMVT icon

Stempoint Capital’s Immunovant IMVT Stock Holding History

Stempoint Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Sell
276,527
-469,967
-63% -$14.3M 1.84% 20
2026
Q1 		$18.5M Buy
746,494
+101,535
+16% +$2.63M 3.55% 5
2025
Q4 		$16.4M Sell
644,959
-944,621
-59% -$21.1M 2.81% 10
2025
Q3 		$25.6M Buy
1,589,580
+288,720
+22% +$4.67M 5.13% 4
2025
Q2 		$20.8M Buy
1,300,860
+447,388
+52% +$6.77M 6.68% 2
2025
Q1 		$14.6M Sell
853,472
-265,036
-24% -$5.54M 4.65% 6
2024
Q4 		$27.7M Buy
1,118,508
+447,507
+67% +$12.7M 6.92% 3
2024
Q3 		$19.1M Sell
671,001
-340,878
-34% -$10.1M 5.73% 4
2024
Q2 		$26.7M Buy
1,011,879
+384,651
+61% +$10.9M 7.85% 3
2024
Q1 		$20.3M Buy
627,228
+305,213
+95% +$11.1M 5.36% 5
2023
Q4 		$13.6M Buy
+322,015
New +$11.8M 3.62% 5

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's IMVT Position: Q2 2026 in Review

Stempoint Capital reduced its Immunovant (IMVT) stake by 63% in Q2 2026, selling an estimated $14.3M and leaving 276,527 shares worth $10.7M. The position accounts for 1.84% of the portfolio, ranked #20.

Stempoint Capital first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. The position peaked at $27.7M in Q4 2024. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Stempoint Capital held 276,527 shares of Immunovant worth $10.7M as of Q2 2026.
  • Stempoint Capital sold 469,967 Immunovant shares in Q2 2026, an estimated $14.3M.
  • Immunovant made up 1.84% of Stempoint Capital's portfolio in Q2 2026, its #20 holding.
  • Stempoint Capital first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • Stempoint Capital's Immunovant position peaked at $27.7M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.